Navigation Links
Hong Kong Cancer Center First in Asia to Commence Treating Cancer Patients Using TrueBeam™ System for Image-Guided Radiotherapy
Date:11/2/2011

HONG KONG, Nov. 2, 2011 /PRNewswire/ -- The Hong Kong Sanatorium & Hospital here has become the first clinic in Asia to commence treating cancer using the TrueBeam™ system from Varian Medical Systems (NYSE: VAR).  Clinicians used the new system on September 28, for the palliative treatment of a metastatic bone lesion, and then again on October 6, to deliver an image-guided and intensity-modulated radiotherapy treatment for a patient battling head and neck cancer.

"The TrueBeam system improves on earlier generations of technology," said Dr. Wing-Hong Kwan, MD, Director of the Department of Radiotherapy at the Hong Kong Sanatorium & Hospital.  "It offers excellent 3-D imaging capabilities so that we can target the tumor with great accuracy.  Using this system, we will be able to quickly deliver high doses to the tumor while limiting exposure of the surrounding tissues and organs."

According to Dr. Kwan, two special capabilities of the TrueBeam system stand out as particularly exciting: the ability to synchronize treatment with a patient's respiratory motion, and the ability to generate real-time images during treatment.  "These capabilities enable us to verify and confirm that we are accurately targeting the tumor throughout a course of treatment," he said.  "They provide us with an added measure of accuracy."

About the TrueBeam SystemTrueBeam was designed to treat tumors with increased speed and accuracy, including tumors that move during treatment as the patient breathes.  It features several technical innovations that dynamically synchronize and integrate imaging, patient positioning, motion management, and treatment delivery during sophisticated treatments for cancer.  With its High Intensity Mode, TrueBeam can accurately deliver high doses, more than twice as fast as earlier generations of technology.  This makes it possible to significantly shorten treatments, potentially enabling clinics to treat more patients each day and to improve precision by leaving less time for tumor motion during dose delivery.

"The TrueBeam system is Varian's most advanced offering for dealing with tumor motion, which makes it especially well-suited for treating cancer of the lung and liver, two types that occur commonly in Asia," said Tom Duffy, head of Varian's Oncology Systems business in Asia. "We are honored to work with the Hong Kong Sanatorium & Hospital, which is very much on the leading edge of cancer care, having adopted this modern technology for the benefit of cancer patients in Hong Kong."

TrueBeam was approved for sale in China by the Chinese State Food and Drug Administration (SFDA) earlier this year.

About Hong Kong Sanatorium & HospitalHong Kong Sanatorium & Hospital is one of the leading private hospitals in Hong Kong. With the motto "Quality in Service Excellence in Care", the Hospital is committed to serving the public as well as promoting medical education and research.

About Varian Medical SystemsVarian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. The company's center in Beijing encompasses oncology equipment manufacturing operations, an educational center for radiotherapy clinical professionals, a customer service center, and X-ray Products assembly and service. For more information, visit http://www.varian.com.FOR INFORMATION CONTACT:  UNITED STATES

ASIAMeryl Ginsberg

Alan TangTel: 1.650.424.6444

Tel: + 852 2369 4280Cell: 1. 650.996.7487

Cell: + 852 9283 2429meryl.ginsberg@varian.com

AlanCY.Tang@varian.com
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):